key: cord-0693420-3j68j67i authors: Kishfy, Louis; Casasola, Marcel; Banankhah, Peymaan; Parvez, Arshi; Jan, Yu Jen; Shenoy, Anant M.; Thomson, Carey; AbdelRazek, Mahmoud A. title: Posterior reversible encephalopathy syndrome in severe SARS-COV-2 infection date: 2020-05-23 journal: J Neurol Sci DOI: 10.1016/j.jns.2020.116943 sha: 241cce6356e223b6ff9b3691182e8d42292145ae doc_id: 693420 cord_uid: 3j68j67i • PRES is potentially a complication of severe SARS-CoV-2 infection. • Consider PRES in COVID-19 patients with altered mentation. • Consider tight blood pressure control in ventilated patients with COVID-19. • Hypertensive encephalopathy may prolong ventilator times in COVID-19 patients. We present a case series of posterior reversible encephalopathy syndrome (PRES) in two patients hospitalized with acute respiratory distress syndrome due to coronavirus disease 2019 , possibly a manifestation of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A 58-year-old man (Patient-1) and a 67-year-old woman (Patient-2) with medical history and hospitalization courses summarized in Table-1 were diagnosed with COVID-19 via a positive nasopharyngeal swab for SARS-CoV-2 nucleic acid. Patient-1 received a single 400 mg intravenous dose of tocilizumab for suspicion of COVID-19-induced cytokine release syndrome. He was weaned off sedation and extubated on day 21. His blood pressure range was 86-189/52-122 mmHg. His post-extubation course was complicated by altered mentation, which gradually improved. Magnetic resonance imaging (MRI) of the brain (Figure 1 ) was done on day 26 and revealed scattered foci of T2 hyperintensity involving the subcortical white matter of both occipital lobes and both posterior temporal lobe with effacement of the adjacent sulci, compatible with PRES. CT head and susceptibility weighted imaging on MRI also revealed convexal subarachnoid hemorrhage, as is often seen with PRES. The patient's blood pressure was then managed with an intravenous nicardipine infusion to <140/90 mmHg for about 24 hours before transitioning to an oral regimen. His mentation continued to slowly improve to his baseline, and he was discharged home on hospital day 33. Patient-2 was weaned off sedation on day 21, but her altered mentation remained the principal barrier to extubation. Her blood pressure range was 79-193/44-97 mmHg. On day 25, MRI brain ( Figure 2 to a weakened blood-brain barrier, which may result in dysfunction of the brain's autoregulation of cerebral circulation. 2, 3 Whether endothelial dysfunction follows a direct toxic insult or is part of an endogenous pathway is unclear. Further supporting an endothelial dysfunction process, one of our patients received tocilizumab, which is known to have endothelial modulation properties and has been previously reported in association with PRES. 4 We have had on average 1.4 cases of PRES per year over the past 5 years (January 2015 to December 2019) in our hospital. The two patients described here were diagnosed in the same week, 3 weeks after the plateau of COVID-19 cases in our hospital. While it is plausible that the occurrence of PRES in these two patients is only incidentally related to their SARS-CoV-2 infection, the weekly average cases of PRES since the plateau of the cumulative curve of COVID-19 cases in our hospital is significantly higher than over the past 5 years (0.66 vs 0.03; p < 0.005, Mann-Whitney rank sum test). A case of COVID-19 associated PRES was recently described in this journal. 5 That patient also had severe SARS-CoV-2 infection requiring mechanical ventilation. While a definitive etiology was likewise not clear in that case, the patient was noted to have elevated blood pressure around the time of PRES diagnosis. Our observations add further evidence to this possible important association. Posterior reversible encephalopathy syndrome Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms Nervous system involvement after infection with COVID-19 and other coronaviruses Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis Sedation of mechanically ventilated COVID-19 patients: challenges and special considerations Transient Cortical Blindness in COVID-19 Pneumonia; a PRES-like Syndrome: Case Report